CONECTA® Platform
Superior starting points, diverse mechanisms
Predictable discovery of highly effective oral medicines that do the job of biologics
The CONECTA® platform is an AI-powered drug discovery platform opening access to the vast diversity of nature-encoded chemistry, turning underexplored molecules into the predictable discovery of advanced oral therapies.
CONECTA® Platform
Predictable path to multiple leads and DCs with diverse chemotypes and mechanisms
Untapped chemistry
We unlock access to a massive, untapped chemical space of over 3 billion unique compounds, opening entirely new opportunities for drug discovery
Biology-first approach
Our approach defines the activity profile needed to address diseases, and our ML enables the discovery of chemistry to precisely match this profile in a mechanism-agnostic way
Unlock complex targets
With our privileged chemistry and platform, complex protein targets are now within reach, including those with no known binding pockets
Untapped bioactive chemical space, unprecedented scale
We are building the world’s largest curated collection of Anthromolecule® compounds – bioactive compounds evolved by nature to have biological activity that humans have safely consumed for centuries. Inspired by their rich three dimensional structures, our proprietary platform retains the uniqueness of this diverse chemistry and evolves it to transform accessibility and broader drug-like properties for efficient discovery.
Discovering chemistry outside the realm of most traditional libraries
3B+ unique compounds
We curated a chemical space rich in three-dimensional structures, with a wider range of vectors to engage complex biology to deliver the desired effect
99% unique scaffolds
Our Anthromolecule library features molecular scaffolds with rich three-dimensional structures with bioactivity history, compelling drug-like properties and accessibility to engage complex biology with precision and selectivity
Multiple mechanisms
Within nature’s vast language is the widest range of mechanisms – from covalent binders, allosteric modulators, molecular glues, and macrocycles to protein-protein interaction inhibitors. The CONECTA® platform opens universal search to find novel solutions for complex biology
Precision pathway connections to target biology
The CONECTA® platform is powered by advanced multimodal foundation models trained on over 1 billion curated and proprietary data points and 100+ biological pathways across five therapeutic areas. By systematically mapping our massive chemical space to the complex biological drivers of disease, the platform enables predictable, repeatable discovery of breakthrough oral medicines.
The CONECTA® platform precision-matches diverse chemistry to deliver target biological outcomes with high efficiency
Superior hit rates
Our platform demonstrates an 80X higher hit rate vs. traditional drug screening, and 9X higher even than industry-leading public machine learning models
60+ predictive models
The CONECTA® platform’s suite of more than 60 state-of-the-art drug property models enables us to deliver superior starting points for our efficient discovery advancement. These integrated models are equal to running 1,000 years of wet-lab experiments in less than two days
Hit to candidate in 24 months
Our platform dramatically accelerates programs with focused medchem, turning hits into potent and selective oral candidates in ~24 months
Integrating human and machine expertise to transform possibilities
Conventional drug discovery happens in silos. The CONECTA® platform unites our entire team of experts across disciplines – biologists, chemists, toxicologists, CMC, and drug developers – to evaluate, optimize and advance programs more efficiently and effectively.
Together with our machine learning experts, this integrated team defines a precise target candidate profile from day one, and then uses AI to rapidly uncover and advance multiple distinct, high potential drug candidates.
AI-powered integrated decisioning weighs risks, trade-offs, and benefits at once—breaking silos for better options
Supercharged drug developers
Our AI platform enables our scientists to define and advance precision drug profiles with efficiency and speed, and agentic tools at each step reduce operational overhead by 80%
Smarter candidates
Our honed inter-disciplinary decisions at each step enabled by AI offer drug developers unprecedented optionality to discover and advance the best possible candidates to deliver precise biological outcomes
Higher probability of success
By delivering multiple independent candidates across a range of disease targets, we aim to maximize our clinical optionality and significantly de-risk our pipeline
Raising the odds of success
Through a highly integrated, AI-driven approach, the CONECTA® platform empowers our drug developers to unearth effective, safe and accessible oral solutions that can solve the hardest biological challenges in chronic inflammatory disease.
See the productivity of the CONECTA® platform in our pipeline.